Viread will be marketed as a therapy for chronic disease in adults.

Gilead Sciences received FDA sanction for its chronic hepatitis B treatment Viread®. The drug works by blocking HBV  DNA polymerase, the enzyme that is necessary for the virus to replicate in liver cells.

Viread will be marketed as a once-daily regimen. Earlier this year, it was approved for chronic hepatitis B in the EU, Turkey, Australia, and New Zealand. A marketing application is currently pending in Canada, reports Gilead.

Viread is also indicated for HIV infection in adults. It has been on the U.S. market since 2001. The hepatitis B approval expands Gilead’s hepatic health franchise, which also includes Hepsera for chronic hepatitis B.

Previous articleCPEX Pharmaceuticals Signs On DPT Laboratories to Produce Insulin Product
Next articleScientists Link an miRNA to Control and Maintainance of Blood-Vessel Development